证券代码：833819 证券简称：颖泰生物 公告编号：2024-015 北京颖泰嘉和生物科技股份有限公司 关于 2023 年度募集资金存放与实际使用情况的专 项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 根据中国证监会发布的《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求（2022 年修订）》和北京证券交易 所颁布的《北京证券交易所股票上市规则（试行）》等有关规定，按 照北京颖泰嘉和生物科技股份有限公司（以下简称"公司"）制定的 《募集资金管理制度》相关要求，公司董事会编制了截至 2023 年 12 月 31 日募集资金存放与实际使用情况的专项报告。 一、募集资金基本情况 公司于 2020 年 2 月 13 日召开第二届董事会第十次会议、2020 年 2 月 28 日召开 2020 年第一次临时股东大会，审议通过了《关于申 请向不特定合格投资者公开发行股票并在精选层挂牌的方案的议 案》。 2020 年 6 月 12 日，北京颖泰嘉和生物科技股份有限公司（以下 简称"公司" ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥5.87 billion, a decrease of 28.09% compared to ¥8.16 billion in 2022[22]. - The net profit attributable to shareholders for 2023 was approximately ¥95.68 million, down 90.95% from ¥1.06 billion in 2022[22]. - The gross profit margin for 2023 was 17.12%, a decline from 26.04% in 2022[22]. - The net profit after deducting non-recurring gains and losses was approximately ¥49.20 million, a decrease of 95.43% compared to ¥1.08 billion in 2022[22]. - The basic earnings per share for 2023 was ¥0.08, down 90.70% from ¥0.86 in 2022[22]. - The weighted average return on net assets based on net profit attributable to shareholders was 1.63% in 2023, down from 19.59% in 2022[22]. - Net profit decreased by 91.38% to ¥3,370,210.53 in Q3 2023, down from ¥79,586,511.58 in Q2 2023[29]. - Operating income fell by 28.09% to ¥7,353,730,720.48 compared to ¥7,425,673,239.60 in the previous year[35]. - Cash flow from operating activities plummeted by 97.38% to ¥38,227,051.23 from ¥1,461,041,757.17[25]. - The interest coverage ratio dropped significantly to 1.82 from 7.39 in the previous year[25]. - The company's inventory turnover ratio decreased to 2.48 from 3.45 year-over-year[25]. - The company achieved revenue of ¥5,868,305,351.83, a decrease of ¥2,292,640,571.12 (approximately 28.1%) compared to the previous year's revenue of ¥8,160,945,922.95[51]. - The net profit attributable to shareholders was ¥95,683,463.98, down by ¥961,577,931.54 (approximately 91.0%) from ¥1,057,261,395.52 in the previous year[51]. - Main business revenue was CNY 5,774,742,867.41, a decrease of 28.14% compared to CNY 8,035,835,483.16 in the previous year[71]. Assets and Liabilities - Total assets increased by 0.72% to ¥12,642,144,017.44 compared to ¥12,551,314,670.01 in the previous year[25]. - Total liabilities rose by 3.55% to ¥6,853,604,881.19 from ¥6,618,844,117.47[25]. - Long-term borrowings increased by 303.74% to CNY 767.54 million, primarily to support project construction[64]. - The company has a total asset value of ¥12,642,144,017.44, an increase of ¥90,829,347.43 from the previous year[52]. Research and Development - The company is engaged in the research, production, and sales of pesticide intermediates, active ingredients, and formulations, as well as GLP registration services and biotechnology research and development[17]. - The company maintains a comprehensive business model focused on R&D and market demand in the agrochemical sector[38]. - The company collaborates closely with clients during the R&D process to meet customer requirements and expand its business[39]. - The company has established a mature independent innovation system with a focus on R&D, covering biotechnology, plant protection, and technical analysis, and has participated in several national key R&D projects[43]. - R&D expenditure for the current period amounted to ¥166,540,895.64, representing 2.84% of operating revenue, an increase from 2.57% in the previous period[102]. - The total number of R&D personnel increased from 492 to 548, with the proportion of R&D staff to total employees rising from 9.78% to 11.14%[104]. - The company holds a total of 383 patents, up from 350 in the previous period, including 196 invention patents, an increase from 177[105]. - The company is collaborating with Tianjin University on the development of new pesticide co-crystal products, providing research funding and technical materials[108]. - The company is also involved in a key national research project with Jiangsu Yangnong Chemical, focusing on the efficient green industrialization of new immune activators[108]. Market and Competition - The agricultural chemicals industry is expected to face continued downward pressure in the short term, but long-term demand for pesticides remains stable due to global food security needs[58]. - The company has maintained a stable market position, ranking among the top ten in China's pesticide sales for the past decade and within the top twenty globally for the last five years[60]. - The company is focusing on enhancing customer relationships and expanding its market presence through marketing transformation and supply chain integration[59]. - The company is actively expanding its market channels, particularly in the U.S. and Europe, through its partnership with ALBAUGH[94]. - The company has implemented strategies to address market competition and improve product profitability amidst industry challenges[95]. Environmental Responsibility - The company is committed to achieving carbon neutrality and sustainability goals, aligning its operations with national climate objectives[131]. - Environmental protection measures include compliance with pollution regulations and initiatives to reduce waste and emissions through process optimization and technology upgrades[130]. - The company has implemented measures to ensure compliance with the GB 39727-2020 standards for air pollutants[134]. - The company is focusing on continuous improvement in wastewater treatment processes to enhance environmental performance[134]. - The company has obtained environmental management system certification (GB/T24001-2016/ISO14001:2015) and maintains compliance with environmental regulations[150]. - The company has established an emergency response system for environmental incidents and conducted regular drills[156]. - The company has implemented a comprehensive wastewater treatment process, including physical and biochemical methods, achieving GB8978-1996 Class II standards[144]. Corporate Governance and Social Responsibility - The company has implemented a comprehensive internal control and governance structure to ensure compliance with relevant laws and regulations, enhancing operational transparency and investor relations[125]. - Employee welfare initiatives include flexible work hours, holiday bonuses, and health check-ups, alongside support for employees facing family hardships[126]. - The company has established a commercial ethics management system to protect the rights of suppliers and customers, fostering a fair and cooperative business environment[127]. - The company has actively participated in poverty alleviation and rural revitalization efforts, providing financial support for local infrastructure and healthcare, contributing to improved living standards in assisted villages[121]. - Subsidiaries have made charitable donations to local Red Cross and charity organizations, reinforcing the company's commitment to social responsibility[122]. Risk Management - The company faces risks related to shareholder control, governance, macroeconomic fluctuations, and tax policy changes, with specific countermeasures in place[172]. - The company is exposed to foreign exchange risks due to a significant portion of product sales being denominated in USD, and it has implemented measures to mitigate these risks[175]. - The company has established a risk-oriented internal management system to address environmental protection risks and has increased investment in environmental research and equipment[175]. - The company has established a comprehensive accident warning and handling mechanism to minimize the likelihood of safety incidents[175]. Future Strategies - The company aims to enhance agricultural production and ensure food security, focusing on sustainable development and core product competitiveness[163]. - From 2023 to 2024, the company emphasizes the necessity of strategic planning in response to challenging market conditions[164]. - The company plans to concentrate resources on core products and production bases to stabilize its operational foundation[165]. - Cost control measures will be implemented through technological innovation and lean production practices to optimize expenses[167]. - Organizational structure optimization will be pursued to enhance efficiency and employee engagement[168].

证券代码：833819 证券简称：颖泰生物 公告编号：2024-004 北京颖泰嘉和生物科技股份有限公司 关于使用闲置募集资金暂时补充流动资金归还的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律 责任。 北京颖泰嘉和生物科技股份有限公司（以下简称"公司"）于 2023 年 4 月 25 日召开了第三届董事会第二十三次会议、第三届监事会第 十七次会议，审议通过了《关于使用闲置募集资金暂时补充流动资金 的议案》，同意公司使用最高额度不超过人民币 10,000 万元的闲置募 集资金暂时补充流动资金，使用期限自公司董事会审议通过之日起不 超过 12 个月，到期前归还至募集资金专用账户。详细内容见公司于 2023 年 4 月 26 日在北京证券交易所指定信息披露平台披露的《关于 使用闲置募集资金暂时补充流动资金公告》（公告编号：2023-033）。 截至 2024 年 3 月 29 日，公司已将用于暂时补充流动资金的 10,000 万元募集资金全部归还并转入募集资金专用账户，使用期限 未超过 12 个月。公司已将上 ...

市场准入优势+转基因育种研究完成生产性试验，凸显公司核心竞争力 | --- | --- | --- | --- | --- | --- | |--------------------------------|-------|-------|-------|-------|-------| | 指标 | 2021A | 2022A | 2023E | 2024E | 2025E | | 营业收入 ( 百万元 ) | 7,426 | 8,161 | 5,905 | 6,956 | 7,961 | | YOY(%) | 19.3 | 9.9 | -27.6 | 17.8 | 14.5 | | 归母净利润 ( 百万元 ) | 476 | 1,057 | 95 | 200 | 405 | | YOY(%) | 46.4 | 121.9 | -91.0 | 110.0 | 103.0 | | 毛利率 (%) | 19.9 | 26.0 | 16.1 | 16.8 | 18.5 | | 净利率 (%) | 6.1 | 13.0 | 1.6 | 2.9 | 5.1 | | ROE(%) | 9.4 | 17.8 | 1.6 ...

Financial Performance - The company expects a net profit attributable to shareholders in the range of 90 million to 110 million CNY, representing a decrease of approximately 89.59% to 91.48% compared to the same period last year, where the profit was 1,056.89 million CNY[4]. - The decline in performance is attributed to factors such as a slowdown in downstream customer demand, industry destocking, and intensified market competition[5]. - The company's market sales scale has contracted, and product profitability has decreased year-on-year due to the adverse market conditions[6]. - The financial data presented is preliminary and has not been audited, with the final figures to be disclosed in the annual report[2][7].

Financial Performance - The company's operating revenue for 2023 is approximately ¥5.91 billion, a decrease of 27.64% compared to the previous year[4] - The net profit attributable to shareholders is approximately ¥95.09 million, down 91.00% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses is approximately ¥60.30 million, a decline of 94.40% compared to the previous year[4] - Basic earnings per share are estimated at ¥0.08, a decrease of 90.70% from the previous year[4] Assets and Equity - Total assets at the end of the reporting period are approximately ¥12.54 billion, a slight decrease of 0.03% from the beginning of the period[5] - Shareholders' equity attributable to the company is approximately ¥5.79 billion, down 2.22% from the beginning of the period[5] - The net asset per share attributable to shareholders is estimated at ¥4.72, a decrease of 2.28% from the beginning of the period[5] Performance Factors - The significant decline in performance is attributed to factors such as reduced downstream customer demand, industry destocking, and intensified market competition[7] - Despite efforts to leverage collaborative advantages in production and sales, the company's performance was still impacted[8] Financial Reporting - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the annual report[9]

| 2024-02- 02 | 833819 | 颖泰生物 | 4.62 | 120000 | 山西证券股份有限公 | 中信证券股份有限公 司北京安外大街证券 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | 司太原上肖墙路证券 | | | 日期 | 代码 | 简称 | 成交价 | 成交数量（股） | 买入营业部 营业部 | 卖出营业部 营业部 | ...

证券代码：833819 证券简称：颖泰生物 公告编号：2023-083 北京颖泰嘉和生物科技股份有限公司 2023 年第三次临时股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 4.会议召集人：董事会 5.会议主持人：王榕 6.召开情况合法、合规、合章程性说明： 本次股东大会会议召开符合《公司法》等有关法律、行政法规、 部门规章、规范性文件和《公司章程》的规定。本次会议召开不需要 相关部门批准。 （二）会议出席情况 出席和授权出席本次股东大会的股东共 12 人，持有表决权的股 份总数 752,055,057 股，占公司有表决权股份总数的 61.3522%。 1.会议召开时间：2023 年 12 月 26 日 2.会议召开地点：公司会议室 3.会议召开方式：现场投票和网络投票结合方式召开 其中通过网络投票参与本次股东大会的股东共 7 人，持有表决权 的股份总数 1,521,546 股，占公司有表决权股份总数的 0.1241%。 （三）公司董事、监 ...

关于北京颖泰嘉和生物科技股份有限公司 北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 北京市康达律师事务所 2023 年第三次临时股东大会的法律意见书 康达股会字[2023]第 0742 号 致：北京颖泰嘉和生物科技股份有限公司 北京市康达律师事务所（以下简称"本所"）接受北京颖泰嘉和生物科技股份 有限公司（以下简称"公司"）的委托，指派本所律师参加公司 2023 年第三次临 时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简 ...

证券代码：833819 证券简称：颖泰生物 公告编号：2023-078 一、 公司及控股子公司向银行等金融机构申请综合授信额度的基 本情况 （一）概述 2024 年度北京颖泰嘉和生物科技股份有限公司（以下简称"公 司"）及控股子公司拟向银行等金融机构申请综合授信的额度总计不 超过 89.75 亿元人民币，综合授信用于办理流动资金贷款、项目资金 贷款、银行承兑汇票、国内信用证、打包贷款、应收账款保理、进出 口押汇、商业票据贴现、银行保函等各种贷款及贸易融资业务。公司 董事会授权公司管理层根据实际情况在前述总授信额度内，办理公司 及控股子公司的融资事宜，并签署有关与各家银行等金融机构发生业 务往来的相关法律文件。 授权期限自公司股东大会审议通过之日起至 2024 年 12 月 31 日 止。 本年度授信额度不等于公司及控股子公司（包括下表未列示的控 股子公司）的实际融资金额，实际融资金额在总授信额度内，以银行 等金融机构与公司及控股子公司实际发生的融资金额为准。公司及控 股子公司间的授信额度可调剂。 单位名称 2024 年度授信金额 （万元） 币种 起止日期 担保方式 北京颖泰嘉和生物科技 股份有限公司 400, ...